|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NFKBID |
Gene summary for NFKBID |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NFKBID | Gene ID | 84807 |
| Gene name | NFKB inhibitor delta | |
| Gene Alias | IkBNS | |
| Cytomap | 19q13.12 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q8NI38 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84807 | NFKBID | LZE4T | Human | Esophagus | ESCC | 4.11e-02 | 7.98e-02 | 0.0811 |
| 84807 | NFKBID | LZE8T | Human | Esophagus | ESCC | 2.39e-06 | 1.05e-01 | 0.067 |
| 84807 | NFKBID | LZE21T | Human | Esophagus | ESCC | 1.58e-02 | 1.20e-01 | 0.0655 |
| 84807 | NFKBID | P1T-E | Human | Esophagus | ESCC | 1.33e-04 | 6.22e-01 | 0.0875 |
| 84807 | NFKBID | P2T-E | Human | Esophagus | ESCC | 2.56e-13 | 2.48e-01 | 0.1177 |
| 84807 | NFKBID | P4T-E | Human | Esophagus | ESCC | 9.94e-05 | 2.36e-01 | 0.1323 |
| 84807 | NFKBID | P5T-E | Human | Esophagus | ESCC | 6.60e-08 | 2.32e-01 | 0.1327 |
| 84807 | NFKBID | P8T-E | Human | Esophagus | ESCC | 8.53e-28 | 6.86e-01 | 0.0889 |
| 84807 | NFKBID | P9T-E | Human | Esophagus | ESCC | 3.97e-07 | 2.94e-01 | 0.1131 |
| 84807 | NFKBID | P10T-E | Human | Esophagus | ESCC | 3.06e-08 | 1.20e-01 | 0.116 |
| 84807 | NFKBID | P12T-E | Human | Esophagus | ESCC | 8.20e-05 | 1.01e-01 | 0.1122 |
| 84807 | NFKBID | P15T-E | Human | Esophagus | ESCC | 1.30e-06 | 1.36e-01 | 0.1149 |
| 84807 | NFKBID | P16T-E | Human | Esophagus | ESCC | 6.16e-05 | 8.15e-02 | 0.1153 |
| 84807 | NFKBID | P21T-E | Human | Esophagus | ESCC | 9.09e-05 | 2.03e-01 | 0.1617 |
| 84807 | NFKBID | P23T-E | Human | Esophagus | ESCC | 1.92e-08 | 5.37e-01 | 0.108 |
| 84807 | NFKBID | P26T-E | Human | Esophagus | ESCC | 6.11e-07 | 9.72e-02 | 0.1276 |
| 84807 | NFKBID | P27T-E | Human | Esophagus | ESCC | 4.35e-05 | 1.95e-01 | 0.1055 |
| 84807 | NFKBID | P28T-E | Human | Esophagus | ESCC | 1.73e-11 | 2.86e-01 | 0.1149 |
| 84807 | NFKBID | P30T-E | Human | Esophagus | ESCC | 2.37e-05 | 2.44e-01 | 0.137 |
| 84807 | NFKBID | P31T-E | Human | Esophagus | ESCC | 1.60e-05 | 1.96e-01 | 0.1251 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
| GO:1903706110 | Esophagus | ESCC | regulation of hemopoiesis | 201/8552 | 367/18723 | 2.60e-04 | 1.58e-03 | 201 |
| GO:19021076 | Esophagus | ESCC | positive regulation of leukocyte differentiation | 93/8552 | 157/18723 | 4.20e-04 | 2.39e-03 | 93 |
| GO:19037086 | Esophagus | ESCC | positive regulation of hemopoiesis | 93/8552 | 157/18723 | 4.20e-04 | 2.39e-03 | 93 |
| GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
| GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
| GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
| GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
| GO:00508528 | Esophagus | ESCC | T cell receptor signaling pathway | 73/8552 | 123/18723 | 1.54e-03 | 7.24e-03 | 73 |
| GO:190210510 | Esophagus | ESCC | regulation of leukocyte differentiation | 152/8552 | 279/18723 | 1.82e-03 | 8.35e-03 | 152 |
| GO:00456213 | Esophagus | ESCC | positive regulation of lymphocyte differentiation | 61/8552 | 104/18723 | 5.22e-03 | 1.97e-02 | 61 |
| GO:005087015 | Esophagus | ESCC | positive regulation of T cell activation | 117/8552 | 216/18723 | 7.23e-03 | 2.62e-02 | 117 |
| GO:00302176 | Esophagus | ESCC | T cell differentiation | 137/8552 | 257/18723 | 8.09e-03 | 2.87e-02 | 137 |
| GO:190303916 | Esophagus | ESCC | positive regulation of leukocyte cell-cell adhesion | 128/8552 | 239/18723 | 8.40e-03 | 2.96e-02 | 128 |
| GO:000715918 | Esophagus | ESCC | leukocyte cell-cell adhesion | 192/8552 | 371/18723 | 1.03e-02 | 3.51e-02 | 192 |
| GO:190303717 | Esophagus | ESCC | regulation of leukocyte cell-cell adhesion | 174/8552 | 336/18723 | 1.36e-02 | 4.43e-02 | 174 |
| GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
| GO:004578520 | Oral cavity | OSCC | positive regulation of cell adhesion | 225/7305 | 437/18723 | 6.06e-08 | 1.09e-06 | 225 |
| GO:004211016 | Oral cavity | OSCC | T cell activation | 245/7305 | 487/18723 | 2.00e-07 | 3.22e-06 | 245 |
| GO:19031316 | Oral cavity | OSCC | mononuclear cell differentiation | 210/7305 | 426/18723 | 8.44e-06 | 9.02e-05 | 210 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NFKBID | SNV | Missense_Mutation | c.883G>A | p.Glu295Lys | p.E295K | Q8NI38 | protein_coding | deleterious(0.01) | possibly_damaging(0.607) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| NFKBID | SNV | Missense_Mutation | rs748957539 | c.773N>T | p.Pro258Leu | p.P258L | Q8NI38 | protein_coding | tolerated(0.32) | possibly_damaging(0.598) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NFKBID | SNV | Missense_Mutation | rs768512398 | c.506G>A | p.Arg169His | p.R169H | Q8NI38 | protein_coding | tolerated(0.62) | benign(0) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NFKBID | SNV | Missense_Mutation | novel | c.644N>G | p.Val215Gly | p.V215G | Q8NI38 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| NFKBID | SNV | Missense_Mutation | c.185N>A | p.Arg62His | p.R62H | Q8NI38 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NFKBID | SNV | Missense_Mutation | novel | c.241C>T | p.Arg81Cys | p.R81C | Q8NI38 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| NFKBID | SNV | Missense_Mutation | rs764013048 | c.794G>A | p.Arg265Gln | p.R265Q | Q8NI38 | protein_coding | tolerated(0.41) | benign(0.145) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NFKBID | SNV | Missense_Mutation | novel | c.799C>A | p.Leu267Met | p.L267M | Q8NI38 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| NFKBID | SNV | Missense_Mutation | novel | c.367C>T | p.His123Tyr | p.H123Y | Q8NI38 | protein_coding | deleterious(0) | benign(0.305) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| NFKBID | SNV | Missense_Mutation | novel | c.51G>T | p.Gln17His | p.Q17H | Q8NI38 | protein_coding | tolerated(0.15) | benign(0.259) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |